MOLOGEN AG
MOLOGEN to present two posters at ESMO WCGI 2014
MOLOGEN AG / Key word(s): Miscellaneous MOLOGEN to present two posters at ESMO WCGI 2014 Berlin, June 12, 2014 – Two poster presentations on clinical trials with the cancer immune therapy MGN1703 of the biotechnology company MOLOGEN AG have been accepted for presentation at the ESMO 16th World Congress on Gastrointestinal Cancer (WCGI) in Barcelona (June 25 – 28, 2014). Updated data on patients with long-term progression-free survival from the phase II IMPACT trial with MGN1703 in colorectal cancer will be presented. This poster has been selected by the ESMO committee for poster discussion. In addition, a second poster will be featured on the design of IMPALA, the subsequent pivotal study. All abstracts from the ESMO 16th World Congress on Gastrointestinal Cancer will be published in a supplement to the Annals of Oncology journal. Abstract details: Abstract number: P-0268 (used in the Exhibition Hall and in the journal) For more information on the ESMO 16th World Congress on Gastrointestinal Cancer please visit ESMO’s website www.esmo.org. About IMPACT Patients included in the IMPACT study had stabilization, or partial or complete remission of their disease after receiving first-line therapy for 4.5 to 6 months. During the study, patients were randomized to receive either MGN1703 or placebo twice per week. The treatment was continued until tumor progression was observed. The primary endpoint of the study was to determine progression-free survival of the patients. Secondary study endpoints included overall survival, progression-free survival from start of induction therapy, response rates and safety, as well as collection of immunological and pharmacodynamic data. About IMPALA The primary endpoint is overall survival and secondary study endpoints include progression-free survival from start of induction therapy, toxicity and safety, and Quality of Life (QoL). About MGN1703 About MOLOGEN AG The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR-9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial applied for) and lung cancer (randomized controlled trial started). Second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. With unique, patented technologies and innovative products, MOLOGEN is pioneering immune therapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com Memberships in associations: MIDGE(R), dSLIM(R), EnanDIM(R)^ and MOLOGEN(R) are registered trademarks of MOLOGEN AG.
PRESS SERVICE: INVESTOR RELATIONS: External Investor Relations: Note about risk for future predictions End of Corporate News 12.06.2014 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | info@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart | |
End of News | DGAP News-Service |
273240 12.06.2014 |